Cellular Senescence-Targeted Therapeutics (Senolytics) in 2026: Selected Positive Phase 2 Signal Alongside Multiple Mixed and Negative Readouts

Senolytics — drugs designed to clear senescent cells — remain in early-to-mid clinical development with mixed Phase 2 readouts; no senolytic is approved for any indication as of 2026, and aging-biology framing of these trials does not imply an 'aging' indication.

Type

evidence-claim

Domain

h08_cellular_senescence

Grade

C+

License

CC BY-NC 4.0

card_id

L-014

hallmarks

h08_cellular_senescence

cluster

clinical_translation

primary_disease_area

longevity_general

evidence_tier

C+

evidence_anchor_count

5

intake_round

R23

intake_date

2026-05-26

related_experts

related_biomarkers

related_interventions

dasatinib_quercetin,ubx1325_foveotinib

related_trials

NCT02874989,NCT04313634

collection_pages

/research/hallmarks/h08-cellular-senescence,/research/interventions/senolytics

LongProof Longevity Dynamic · LIGHT HOPE / x1000.ai · longevity.x1000.ai · 2026 · source

Read-only aggregated view. Longevity Evidence is the source of record; this catalog shows provenance as-is — no ratings, no reviews.